Werfen Life Group, S.A
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Werfen Life Group, S.A - overview
Established
1966
Location
Barcelona, -, Spain
Primary Industry
Medical Devices & Equipment
About
Werfen Life Group, S. A operates as a developer of innovative diagnostic systems focused on enhancing patient care. Founded in 1966 and headquartered in Barcelona, Spain, the company has consistently evolved its business operations to meet the needs of the healthcare sector. The current CEO is Carlos Pascual, who oversees the strategic direction of the company.
Werfen specializes in advanced diagnostics and medical technologies, focusing on several core product lines that cater to the healthcare sector. Their Hemostasis product line includes in vitro diagnostic systems, reagents, and services designed to assist in the diagnosis and management of thrombotic and bleeding disorders. These solutions are utilized by laboratories and hospitals worldwide to enhance patient care and ensure regulatory compliance. The company also offers Acute Care Diagnostics, which provides integrated whole blood testing systems aimed at improving efficiency in critical care environments, such as emergency departments and intensive care units.
Their Transfusion portfolio ensures the compatibility of blood transfusions through a comprehensive suite of serology reagents and automated instrumentation, while their Autoimmunity and Transplant product lines focus on enhancing the diagnosis and treatment of autoimmune diseases and transplant compatibility, respectively. Werfen's products are actively sold in various international markets, including North America, Europe, Latin America, the Middle East, and Asia. In the most recent year, 2022, Werfen generated revenue of USD 191. 61 mn, with an EBITDA of USD 91.
46 mn. The company generates revenue through direct sales of its diagnostic systems and reagents to healthcare institutions and laboratories, employing a B2B transaction structure with long-term contracts and agreements.
Primary Industry
Medical Devices & Equipment
Sub Industries
Diagnostic, Medical & Imaging Laboratories, Diagnostic Equipment, Medical Equipment Distributors, Medical Supplies, Medical Software
Website
www.werfen.com
Verticals
Manufacturing
Total Amount Raised
Subscriber access only
Werfen Life Group, S.A - timeline of key events
Werfen Life Group, S.A - financials
| Fiscal Year Ended | Dec 31, 2015 | Dec 31, 2016 | Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | 45,815,000 | 88,811,000 | 133,276,000 | 100,590,000 | 424,618,000 | 299,863,000 | 1,853,502,000 | - | - | - |
| % Revenue Growth (YoY) | - | 93.8% | 50.1% | (24.5%) | 322.1% | (29.4%) | 518.1% | - | - | - |
| EBITDA (USD) | (2,457,000) | 35,135,000 | 68,826,000 | 33,136,000 | 362,570,000 | 210,512,000 | 599,272,000 | - | - | - |
| Operating Income (USD) | (3,738,000) | 33,591,000 | 67,048,000 | 31,270,000 | 360,613,000 | 208,508,000 | 466,159,000 | - | - | - |
| Operating Margin | (8.2%) | 37.8% | 50.3% | 31.1% | 84.9% | 69.5% | 25.2% | - | - | - |
| % EBITDA Margin | (5.4%) | 39.6% | 51.6% | 32.9% | 85.4% | 70.2% | 32.3% | - | - | - |
| NET Income (USD) | (22,434,000) | 16,333,000 | 23,210,000 | 21,955,000 | 354,585,000 | 208,635,000 | 362,901,000 | - | - | - |
| % Net Margin | (49.0%) | 18.4% | 17.4% | 21.8% | 83.5% | 69.6% | 19.6% | - | - | - |
Werfen Life Group, S.A - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Trade Sale | Completed | Immucor, Inc. | - | ||||||||
| Trade Sale | Completed | Accriva Diagnostics | - |
Displaying 1 - 2 of 2
Werfen Life Group, S.A - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.